1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,960 | 6,000 | 11:57 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 14.04. | Availability of MaaT Pharma's 2024 Universal Registration Document (URD) | 170 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 08.04. | MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 217 | Business Wire | Following a milestone unblinded interim safety review, the independent Data Safety Monitoring Board (DSMB) has recommended that the study proceed without modification. MaaT033, a pooled... ► Artikel lesen | |
| 07.04. | MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co | 346 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 04.04. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 269 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 31.03. | MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients' Responses to Immunotherapies | 234 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 27.03. | MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results | 749 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results (January 2025) showed a 62% gastrointestinal overall response rate at Day 28 and 1-year... ► Artikel lesen | |
| 19.03. | MaaT Pharma stock adds 7% on DSMB nod | 3 | Investing.com | ||
| 18.03. | MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease | 271 | Business Wire | The Independent Data Safety and Monitoring Board (DSMB) confirmed the remarkable efficacy results and a positive benefit/risk profile of MaaT013 in this patient population
The Company plans... ► Artikel lesen | |
| 11.03. | MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013 | 380 | Business Wire | Positive EMA Pediatric Committee opinion has cleared the investigation clinical plan to evaluate the safety and efficacy of MaaT013 in patients from 6 years old to less than 18 years old with... ► Artikel lesen | |
| 21.01. | MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 432 | Business Wire | The Independent Data Safety and Monitoring Board (DSMB) has recommended that the trial proceeds as planned without modification. Consistent good safety profile and tolerability for MaaT033... ► Artikel lesen | |
| 08.01. | MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease | 576 | Business Wire | The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of MaaT013 as third-line treatment of aGvHD... ► Artikel lesen | |
| 07.01. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 356 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 10.12.24 | MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting | 365 | Business Wire | MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) Register here.
Sustained High Response Rates... ► Artikel lesen | |
| 05.12.24 | MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease | 583 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 26.11.24 | MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | 88 | Business Wire | MaaT033 administered for two months confirmed good safety profile and was well tolerated in patients with ALS. Other study endpoints will be analysed in the upcoming months with full data... ► Artikel lesen | |
| 07.11.24 | MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD | 458 | Business Wire | Efficacy, safety, and long-term follow-up data from 154 patients in the EAP in Europe further reinforce the excellent clinical profile of MaaT013 in GI-aGvHD.
MaaT013 is a safe and effective... ► Artikel lesen | |
| 05.11.24 | MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes | 379 | Business Wire | Completion of enrollment in the European Phase 3 clinical trial ARES designed to evaluate efficacy and safety of MaaT013 in the treatment of acute Graft-versus-Host Disease; topline results expected... ► Artikel lesen | |
| 15.10.24 | MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease | 297 | Business Wire | Last patient treated in MaaT Pharma's Phase 3 ARES clinical trial
Topline results publication now expected in January 2025
Positive DSMB review of Phase 3 ARES trial announced in... ► Artikel lesen | |
| 19.09.24 | MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update | 409 | Business Wire | Positive efficacy and safety data of MaaT013 in aGvHD in the Early Access Program presented at the EBMT 2024 annual meeting with 63% GI-ORR at D28, a 49% one year and 42% 18 months Overall Survival... ► Artikel lesen | |
| 09.09.24 | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 434 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 7,334 | +2,12 % | Intellia Therapeutics shares up after Wolfe upgrade | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,018 | +2,07 % | PacBio, Davos Alzheimers Collaborative Join For North African Dementia Registry Project | WASHINGTON (dpa-AFX) - The Davos Alzheimers Collaborative, a global initiative to prevent Alzheimers disease and improve brain health, announced that PacBio (PACB) will be a technology partner... ► Artikel lesen | |
| CENTOGENE | 0,101 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,333 | -0,52 % | ATAI Life Sciences Aktie: Bericht über jüngste Finanztrends | Das Biotechnologie-Unternehmen erforscht innovative Substanzen gegen Depressionen und entwickelt neuartige Behandlungsmethoden für psychische Erkrankungen. ATAI Life Sciences treibt die Entwicklung... ► Artikel lesen | |
| BIOMERIEUX | 113,50 | -1,05 % | BIOMERIEUX: WATCHFIRE by bioMérieux: a PCR test to detect viruses and bacteria in wastewater and respond to potential infectious disease outbreaks | ||
| CYCLACEL | 0,296 | -100,00 % | Cyclacel Pharmaceuticals declares $0.15 dividend | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,100 | -1,79 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| GENUS | 18,600 | 0,00 % | Dividendenbekanntmachungen (04.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN EXPRESS COMPANY US0258161092 0,82 USD 0,742 EUR BARCLAYS PLC GB0031348658 0,055 GBP EUR BRISTOL-MYERS SQUIBB COMPANY US1101221083 0... ► Artikel lesen | |
| ABIONYX PHARMA | 1,160 | +0,17 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| ANAPTYSBIO | 18,200 | +0,55 % | AnaptysBio, Inc.: Anaptys Announces Stock Repurchase Plan | SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that... ► Artikel lesen | |
| MEIRAGTX | 5,700 | +1,79 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
| AKESO | 11,500 | 0,00 % | Akeso, Inc.: Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma | HONG KONG, April 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,155 | -1,71 % | Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan | Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the... ► Artikel lesen | |
| DIAGONAL BIO | 0,000 | 0,00 % | DIAGONAL BIO AB: Diagonal Bio announces change of news plattform |
MAAT PHARMA SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,040 (+0,68 %) liegt der Kurs bei 5,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.
